These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 37753739)
1. ' H Ibraheim M; Maher I; Khater I J Biomol Struct Dyn; 2024 Nov; 42(18):9571-9586. PubMed ID: 37753739 [TBL] [Abstract][Full Text] [Related]
2. In Silico Repurposing of a Novel Inhibitor (drug) of EGFR and VEGFR-2 Kinases of Cancer by Pharmacokinetics, Toxicity, Molecular Docking, and Molecular Dynamics Simulation. Ibraheim MH; Maher I; Khater I Appl Biochem Biotechnol; 2024 May; ():. PubMed ID: 38782800 [TBL] [Abstract][Full Text] [Related]
3. Computer-aided anti-cancer drug discovery of EGFR protein based on virtual screening of drug bank, ADMET, docking, DFT and molecular dynamic simulation studies. Roney M; Dubey A; Hassan Nasir M; Tufail A; Tajuddin SN; Mohd Aluwi MFF; Huq AM J Biomol Struct Dyn; 2024 Nov; 42(18):9662-9677. PubMed ID: 37676262 [TBL] [Abstract][Full Text] [Related]
4. Computational Investigation of 1, 3, 4 Oxadiazole Derivatives as Lead Inhibitors of VEGFR 2 in Comparison with EGFR: Density Functional Theory, Molecular Docking and Molecular Dynamics Simulation Studies. Bilal MS; Ejaz SA; Zargar S; Akhtar N; Wani TA; Riaz N; Aborode AT; Siddique F; Altwaijry N; Alkahtani HM; Umar HI Biomolecules; 2022 Nov; 12(11):. PubMed ID: 36358960 [TBL] [Abstract][Full Text] [Related]
5. EGFR/VEGFR-2 dual inhibitor and apoptotic inducer: Design, synthesis, anticancer activity and docking study of new 2-thioxoimidazolidin-4one derivatives. Mourad AAE; Farouk NA; El-Sayed EH; Mahdy ARE Life Sci; 2021 Jul; 277():119531. PubMed ID: 33887348 [TBL] [Abstract][Full Text] [Related]
6. Ligand-Based Pharmacophore Modeling, Molecular Docking, and Molecular Dynamic Studies of Dual Tyrosine Kinase Inhibitor of EGFR and VEGFR2. Sangande F; Julianti E; Tjahjono DH Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33096664 [TBL] [Abstract][Full Text] [Related]
7. Targeting EGFR and VEGFR-2 Kinases With Nanoparticles: A Computational Approach for Cancer Therapy Advancement. Khater I; Nassar A Cancer Invest; 2024 Feb; 42(2):176-185. PubMed ID: 38486424 [TBL] [Abstract][Full Text] [Related]
8. Computational identification of new TKI as potential noncovalent reversible EGFR Abdelmalek D; Smaoui F; Frikha F; Ben Marzoug R; Msalbi D; Souissi A; Aifa MS J Biomol Struct Dyn; 2024 Jun; 42(9):4870-4887. PubMed ID: 37349947 [TBL] [Abstract][Full Text] [Related]
9. Kumar S; Ali I; Abbas F; Rana A; Pandey S; Garg M; Kumar D J Biomol Struct Dyn; 2024 Nov; 42(18):9416-9438. PubMed ID: 37646177 [TBL] [Abstract][Full Text] [Related]
10. A series of quinazolin-4(3H)-one-morpholine hybrids as anti-lung-cancer agents: Synthesis, molecular docking, molecular dynamics, ADME prediction and biological activity studies. Tokalı FS; Şenol H; Ateşoğlu Ş; Akbaş F Chem Biol Drug Des; 2024 Jul; 104(1):e14599. PubMed ID: 39039616 [TBL] [Abstract][Full Text] [Related]
11. In silico insights into the identification of potential novel angiogenic inhibitors against human VEGFR-2: a new SAR-based hierarchical clustering approach. Konidala KK; Bommu UD; Pabbaraju N J Recept Signal Transduct Res; 2018 Aug; 38(4):372-383. PubMed ID: 30396316 [TBL] [Abstract][Full Text] [Related]
12. Novel benzothiazole-based dual VEGFR-2/EGFR inhibitors targeting breast and liver cancers: Synthesis, cytotoxic activity, QSAR and molecular docking studies. Abd El-Meguid EA; Naglah AM; Moustafa GO; Awad HM; El Kerdawy AM Bioorg Med Chem Lett; 2022 Feb; 58():128529. PubMed ID: 35007724 [TBL] [Abstract][Full Text] [Related]
13. Development and assessment of novel pyrazole-thiadiazol hybrid derivatives as VEGFR-2 inhibitors: design, synthesis, anticancer activity evaluation, molecular docking, and molecular dynamics simulation. Halimi G; Osmaniye D; Özkay Y; Kaplancıklı ZA Z Naturforsch C J Biosci; 2024 Sep; 79(9-10):291-304. PubMed ID: 38818683 [TBL] [Abstract][Full Text] [Related]